

# 1 Free fatty acids accelerate $\beta$ -cell death in type 1 diabetes

2

3 Emily C. Elliott<sup>1#</sup>, Soumyadeep Sakar<sup>1#</sup>, Lisa Bramer<sup>1</sup>, Meagan Burnet<sup>1</sup>, Young-Mo  
4 Kim<sup>1</sup>, Xiaoyan Yi<sup>2</sup>, Igor L. Estevas<sup>1</sup>, Marian Rewers<sup>3</sup>, Xiaolu A. Cambronne<sup>4</sup>, Kendra  
5 Vehik<sup>5</sup>, Rafael Arrojo e Drigo<sup>6</sup>, Thomas O. Metz<sup>1</sup>, Decio L. Eizirik<sup>2</sup>, Bobbie-Jo M. Webb-  
6 Robertson<sup>1</sup>, Raghavendra G. Mirmira<sup>7</sup>, Ernesto S. Nakayasu<sup>1,\*</sup>

7

8 <sup>1</sup>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA,  
9 USA.

10 <sup>2</sup>ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles  
11 (ULB), Brussels, Belgium.

12 <sup>3</sup>Barbara Davis Center for Diabetes, School of Medicine, University of Colorado  
13 Anschutz Medical Campus, Aurora, CO, USA.

14 <sup>4</sup>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.

15 <sup>5</sup>Health Informatics Institute, Morsani College of Medicine, University of South Florida,  
16 Tampa, Florida, USA.

17 <sup>6</sup>Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville,  
18 TN, USA.

19 <sup>7</sup>Kovler Diabetes Center and Department of Medicine, The University of Chicago,  
20 Chicago, IL, USA.

21

22 #Equally contributing authors.

23 \*Correspondence: [ernesto.nakayasu@pnnl.gov](mailto:ernesto.nakayasu@pnnl.gov) (to E.S.N.)

24

25

26 **Abstract**

27 Type 1 diabetes (T1D) results from autoimmune destruction of the insulin producing  
28 pancreatic  $\beta$  cells. The body's lipid metabolism is strongly regulated during this process  
29 but there is a need to understand how this regulation contributes to the  $\beta$ -cell death.  
30 Here, we show that fatty acids are released from plasma lipoproteins in children during  
31 islet autoimmunity, prior to T1D onset. These fatty acids (FFAs) enhanced cytokine-  
32 mediated apoptosis in cultured insulin-producing cells by downregulating the production  
33 of nicotinamide adenosine dinucleotide (NAD) via its salvage pathway, as well as  
34 deregulated central carbon metabolism and impaired levels of ATP. Downregulation of  
35 the NAD salvage pathway and central carbon metabolism enzymes were further  
36 observed during T1D development, supporting that the pathways for NAD and energy  
37 production are compromised *in vivo*. Our findings show that fatty acids are released  
38 during islet autoimmunity, accelerating disease development through impaired NAD  
39 metabolism.

40

## 41 Introduction

42 Type 1 diabetes (T1D) affects an estimated 8.4 million people worldwide and reduces  
43 the life expectancy of those affected by over a decade<sup>1-3</sup>. The disease results from the  
44 progressive loss of insulin-producing  $\beta$  cells of the pancreas via an autoimmune  
45 response, leading to the inability to control blood glucose levels<sup>4,5</sup>. Selected human  
46 leukocyte antigen (*HLA*) genotypes are risk factors, but only 5% of individuals carrying  
47 those genotypes eventually develop T1D<sup>6-8</sup>, suggesting the contribution of additional  
48 biotic and environmental factors<sup>9</sup>. The body metabolism may be one of these factors as  
49 many of its aspects have been associated with T1D development<sup>9-12</sup>. However, little is  
50 known about how specific metabolic pathways mechanistically contribute to disease  
51 development.

52 Among the metabolic processes, the body lipid metabolism is one of the most regulated  
53 during T1D development<sup>10,12-14</sup>. Plasma lipoproteins are regulated in children even prior  
54 to the onset of islet autoimmunity (herein referred to as seroconversion and clinically  
55 diagnosed by the appearance of circulating islet autoantibodies)<sup>15</sup>. There is also a  
56 decrease in the levels of plasma phosphatidylcholine and triacylglycerols during T1D  
57 development<sup>10</sup>. Similarly, in human islets treated with the pro-inflammatory cytokines IL-  
58  $1\beta$  and IFN- $\gamma$  that mimic the insulinitis environment, there is a decrease in triacylglycerol  
59 levels<sup>16</sup>. Other lipids, such as short-chain fatty acids, drive inflammation of the intestine,  
60 increases intestinal permeability, and augments the exposure to putative dietary  
61 antigens<sup>17</sup>. Conversely, diets enriched in omega-3 fatty acids improve intestinal integrity  
62 and reduce the onset of T1D in mice<sup>18,19</sup>. Omega-3-rich diet can also diminish the risk of  
63 children to develop islet autoimmunity<sup>20</sup>. Mechanistically, omega-3 fatty acids reduce  
64 apoptosis of insulin-producing cells by downregulating the methylation of the *ADPRHL2*  
65 gene and releasing the expression of its product, the anti-apoptotic factor ARH3.

66 An open question is how these regulations in the lipid metabolism contribute to T1D  
67 development. Here, we hypothesize that downregulations of triacylglycerols (in both  
68 plasma and islets) and phosphatidylcholines (in plasma) have a role in  $\beta$ -cell death. To  
69 test this hypothesis, we first analyzed lipidomics and proteomics data from human  
70 plasma and islets to determine possible regulatory mechanisms of these lipid classes.  
71 We also performed experiments in MIN6 insulin-producing cells and analyzed single-cell  
72 transcriptomic data to study the downstream consequences of triacylglycerol and  
73 phosphatidylcholine downregulation in T1D development. Our data show a mechanism  
74 by which lipids accelerate T1D development.

75

## 76 **Material and Methods**

### 77 *Data from a longitudinal cohort of individuals at high risk of developing T1D*

78 *TEDDY Study and lipidomics dataset.* Six clinical research centers - three in the USA  
79 (Colorado, Georgia/Florida, Washington State), and three in Europe (Finland, Germany,  
80 and Sweden) participated in a population-based HLA screening of newborns between  
81 September 1, 2004 and February 28, 2010<sup>21,22</sup>. The HLA high-risk genotypes identified  
82 from the general population (89%) and for infants with a first-degree relative with T1D  
83 were previously described<sup>23</sup>. Children enrolled (n=8,676) were prospectively followed  
84 from three months of age to 15 years with study visits that include a blood draw every  
85 three months until four years and every three or six months thereafter depending on  
86 autoantibody positivity. A nested-matched case-control study was conducted through  
87 risk-set sampling using metadata and autoantibody sample results as of May 31, 2012,  
88 as previously detailed<sup>24</sup>. Additional matching by the clinical center, sex, and family  
89 history of T1D (general population or first-degree relative) were included as criteria in  
90 the selection of controls. The sample selection was determined by the Data  
91 Coordinating Center (University of South Florida Health Informatics Institute, Tampa, FL)  
92 without the lab knowing the case-control status. The characteristics of the donors are  
93 listed in **Supplemental Table 1**. Plasma lipidomics data were reanalyzed from the  
94 datasets described in previous publications<sup>25-27</sup>. The effect of sample analysis order on  
95 quantified lipidomics data was removed by applying Systematic Error Removal using  
96 Random Forest (SERRF)<sup>28</sup>. All missing values were replaced with “NA”, and data were  
97 log<sub>2</sub> transformed. For each time point and lipid combination, a paired *t*-test, accounting  
98 for case-control pairs, was conducted, and a Benjamini-Hochberg false-discovery rate  
99 correction was applied to the resulting p-values<sup>29</sup>.

### 100 *GC-MS analysis*

101 Human islets treated with 50 U/mL human IL-1 $\beta$  + 1000 U/mL human IFN- $\gamma$  (cytokine  
102 cocktail 1 or “CT1”) for 24 h were collected as previously described<sup>30</sup>. The Pacific  
103 Northwest National Laboratory institutional review board deemed the project to not be  
104 human subject research and waived full ethical review. The characteristics of the donors  
105 are listed in **Supplemental Table 2**. The data from this experiment were subsequently  
106 integrated with proteomics and lipidomics data published elsewhere<sup>16,30</sup>. Samples from  
107 either these human islets or MIN6 cells treated as described above were submitted to  
108 simultaneous metabolite, protein, and lipid extraction (MPLEx)<sup>31</sup>. Metabolites were  
109 treated with 30 mg/mL methoxyamine in pyridine for 90 min at 37 °C with shaking, and  
110 derivatized with N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) (Sigma-Aldrich)  
111 with 1% trimethylchlorosilane (TMCS) (Sigma-Aldrich) at 37 °C with shaking for 30  
112 min<sup>32</sup>. Derivatized metabolites were analyzed using an Agilent GC 7890A equipped with  
113 an HP-5 MS column (30 m  $\times$  0.25 mm  $\times$  0.25  $\mu$ m; Agilent Technologies, Santa Clara,

114 CA) and coupled with a single quadrupole MSD 5975C (Agilent Technologies). Samples  
115 were injected into a splitless port set at 250°C with an initial oven temperature of 60 °C.  
116 After 1 min the temperature was increased to 325°C at a rate of 10°C/min, and finished  
117 with a 5-min hold at 325 °C. The data files were calibrated with external calibration of  
118 fatty acid methyl ester and converted to retention time indexes relative to the elution of  
119 the fatty acid methyl esters. Molecules were identified by matching experimental  
120 retention indices and/or mass spectra to an in-house augmented version of FiehnLib,  
121 NIST20, Wiley 11<sup>th</sup> edition, and MS-DIAL databases  
122 (<https://systemsomicslab.github.io/compms/index.html>)<sup>33,34</sup>. Significant differences in  
123 metabolite relative abundances were determined by Student's *t*-test. The central carbon  
124 metabolism pathway was plotted along with each metabolite relative abundance using  
125 Vanted<sup>35</sup>.

#### 126 *Cell culture*

127 MIN6 cells were maintained at 37 °C in a 5% CO<sub>2</sub> atmosphere in DMEM containing 4.5  
128 g/L each of D-glucose and L-glutamine, 10% fetal bovine serum, 100 units/mL penicillin,  
129 100 µg/mL streptomycin, and 50 µM 2-mercaptoethanol. For cell assay experiments,  
130 cells were treated at 80% confluency with a cytokine cocktail (CT2: 100 ng/mL mouse  
131 IFN-γ: R&D, cat#485-MI-100, 10 ng/mL mouse TNF-α: R&D, Cat#410-MT-010, and 5  
132 ng/mL mouse IL-1β: R&D, cat #401-ML-005) for 24 h. Cells were treated concurrently  
133 with various concentrations of palmitate (Cayman, CAS#10006627), 10 µM NAMPT  
134 inhibitor FK866 (MCE, Cat. No.: HY-50876), 200 µM hexokinase inhibitor Ionidamine  
135 (Tocris, Cat. No. 1646), or 100 µM nicotinamide riboside (NR) (MCE, HY-123033A). The  
136 concentration of NAMPT inhibitor, hexokinase inhibitor, and NR was determined by a  
137 dose-response curve, and the concentration with maximum effect was chosen.  
138 Palmitate stock was prepared in ethanol and diluted in 0.5% delipidated bovine serum  
139 albumin to keep it in solution.

#### 140 *Proteomics analysis*

141 MIN6 cells were lysed in 50 mM Tris-HCl containing 8 M urea and 10 mM dithiothreitol  
142 and incubated for 1 h at 37 °C with shaking at 800 rpm. Iodoacetamide was added to a  
143 final concentration of 40 mM from a 400-mM stock, and the sample was incubated for 1  
144 h in the dark at 21 °C. The reaction mixture was diluted 8-fold with 50 mM Tris-HCl, and  
145 1 M CaCl<sub>2</sub> was added to a final concentration of 1 mM. Proteins were digested  
146 overnight at room temperature using sequencing-grade trypsin (Promega) at an  
147 enzyme-to-protein ratio of 1:50. Digested peptides were desalted by solid-extraction in  
148 C18 cartridges (Discovery, 50 mg, Sulpelco) following manufacturer recommendations,  
149 and dried in a vacuum centrifuge. Peptides were analyzed using a Waters NanoAquity  
150 UPLC system coupled with a Q-Exactive mass spectrometer, as previously described<sup>36</sup>.  
151 The data were processed with MaxQuant software (v.1.5.5.)<sup>37</sup> using the mouse

152 reference proteome database from UniProt Knowledge Base (downloaded on  
153 08/31/2023). Protein N-terminal acetylation and oxidation of methionine were set as  
154 variable modifications, while cysteine carbamidomethylation was set as a fixed  
155 modification. The software's default mass shift tolerance was used. Statistical analysis  
156 and heatmap were done using Perseus<sup>38</sup>. MaxLFQ intensity was used to quantify  
157 protein, being log<sub>2</sub> transformed, median normalized, and having the missing values  
158 were imputed with Gaussian distribution<sup>39</sup>. Student's *t*-test was used to determine  
159 statistically different proteins. Functional-enrichment analysis was done for the  
160 statistically significant proteins using DAVID<sup>40</sup>, using all the predicted mouse genes as  
161 the background.

#### 162 *Apoptosis, NAD, and ATP assays*

163 Apoptosis, NAD, and ATP levels were measured with Caspase-Glo, NAD/NADH-Glo,  
164 and CellTiter-Glo® 2.0, respectively, following the manufacturer-provided protocols  
165 (Promega Cat# G8092, G9071, and G9242). MIN6 cells were treated with palmitate,  
166 FK866, lonidamine, or NR, and CT2 for 24 h. The appropriate amount of the assay  
167 reagent was added to the wells. The contents were gently mixed for 30 s and  
168 luminescence was read for 3 h every 30-min interval using a plate reader (Synergy HT,  
169 BioTek). The time point with the highest signal was selected for analysis. All statistical  
170 analysis and data visualization were performed using GraphPad Prism 9 (Version 9.4.1  
171 (458)).

#### 172 *Single cell RNA seq analysis*

173 The raw single-cell RNA-seq data files (FASTQ, 10X Genomics) of human islets<sup>41</sup> were  
174 downloaded from the Human Pancreas Analysis Program (HPAP) data portal  
175 (<https://hpap.pmacs.upenn.edu/>) and processed with Cell Ranger (v6.1.2). The clinical  
176 characteristics of the donors are listed in **Supplementary Table 3**. Data were  
177 processed following 10X Genomics recommendations for quality control, read alignment  
178 to the reference genome (hg38), barcode processing, and molecule counting. Initial  
179 clustering was performed using Seurat software (v4.1.1), followed by decontamination  
180 of background mRNA using SoupX (v1.6.1); key genes (*INS*, *GCG*, *SST*, *TTR*, *IAPP*,  
181 *PYY*, *KRT19*, *TPH1*) representing the major cell types were identified in the initial  
182 clustering. The adjusted gene expression counts were further processed in Seurat for  
183 additional filtering. Potential doublets were identified and removed using scDbIFinder  
184 (v3.16). Cells were filtered based on the following criteria: nFeature\_RNA > 1,000 and <  
185 9,000, mitochondrial gene percentage < 15%, and nCount < 100,000. Following the  
186 steps outlined above, we obtained 91,047 single cells for downstream analysis.  
187 Normalization of counts was done using the R package scTransform, which adjusts for  
188 library size variations per cell. Mitochondrial gene variation was also regressed out, as it  
189 indicates cell state. We selected the top 3,000 variable genes to perform principal

190 component analysis (PCA). Data integration was conducted using Harmony (v0.1.1)  
191 with the top 50 PCA components, accounting for each sample and reagent kit batches  
192 as confounding factors. The integrated components were used to construct a Uniform  
193 Manifold Approximation and Projection (UMAP) embedding of the 91,047 cells. Finally,  
194 cell types were annotated with scSorter (v0.0.2) based on known marker genes.  
195 ExcelChIP-Seq data visualization was performed using IGV software.

196

## 197 **Results**

### 198 ***Pro-inflammatory cytokines induce the release of palmitate in human islets***

199 We have previously shown that triacylglycerols were consistently downregulated in 3  
200 insulinitis models: islets from NOD mice in the prediabetic stage, and EndoC- $\beta$ H1 cells  
201 and human islets treated with a cocktail of pro-inflammatory cytokines (CT1: 50 U/mL  
202 IL-1 $\beta$  and 1000 U/mL IFN- $\gamma$ )<sup>16</sup>. To further study this phenotype, we analyzed our  
203 previously published proteomics dataset from the same human islets<sup>30</sup> and found that  
204 endothelial lipase LIPG was increased 1.4-fold with CT1 treatment (**Fig. 1A**), suggesting  
205 a possible mechanism. A gas chromatography-mass spectrometry analysis of the same  
206 human islets treated with CT1 showed that palmitate was increased 1.7-fold with CT1  
207 treatment (**Fig. 1B**). These data show that CT1 induces the digestion of TGs into free  
208 fatty acids (FFAs).

### 209 ***Increase of free fatty acid levels in plasma from donors with islet autoimmunity***

210 We investigated if TG digestion and fatty acid release also occurs *in vivo*, during T1D  
211 development. As LIPG is a major plasma lipoprotein lipase, we search these signatures  
212 on the plasma lipidomics data of the nested case-control 1 study (NCC1) from The  
213 Environmental Determinants of Diabetes in the Young (TEDDY) study (**Supplemental**  
214 **Table 4**). In TEDDY NCC1, samples were collected every 3 months from individuals  
215 carrying the high-risk HLA alleles from birth until the age of 6 years. We included data  
216 from all 94 children who progressed to clinical T1D and from their matched controls. The  
217 lipidomics data showed a decrease in the levels of 18 of the 127 phosphatidylcholine  
218 species (14%) and 14 of the 100 triacylglycerol species (14%) 3 months post-  
219 seroconversion (**Fig. 2A**). The phosphatidylcholine and triacylglycerol intermediate  
220 cleavage products lysophosphatidylcholines and diacylglycerols, respectively, displayed  
221 a downregulation trend with 3 out of their 32 species (10%) significantly reduced (**Fig.**  
222 **2B**). Among the FFAs, 2 and 4 of their 31 species (19%) were upregulated at the time of  
223 and 3 months post-seroconversion, respectively (**Fig. 2C**). The downstream products  
224 from FFAs, acyl-carnitines, had 3 and 7 of their 17 species (59%) upregulated at the  
225 time of and 3 months post-seroconversion, respectively (**Fig. 2C**). This suggests that

226 the extent of fatty acid release is higher than the one observed based on FFA  
227 abundance alone.

228 We also examined the abundance of key lipoprotein subunits and lipases in TEDDY  
229 NCC1 proteomics data<sup>15</sup>. Apolipoprotein ApoA1 was upregulated pre-seroconversion,  
230 whereas ApoA2, ApoB, ApoC1, ApoC2 and ApoC3 were downregulated post-  
231 seroconversion (**Fig. 2D**). Regarding lipases, the lipoprotein lipase LPL and the hepatic  
232 lipase LIPC had similar abundances pre- and post-seroconversion compared to the  
233 control group (**Fig. 2D**). LIPG was not detected in the analysis.

234 Overall, these data suggest a digestion of phosphatidylcholines and triacylglycerols,  
235 leading to the release of FFAs. These changes are accompanied by reduction in  
236 multiple lipoprotein subunits.

### 237 ***Palmitate enhances pro-inflammatory cytokine-mediated apoptosis.***

238 To study if the FFAs have a role in  $\beta$ -cell death, we measured apoptosis in MIN6 cells  
239 treated with a cytokine cocktail (CT2: 100 ng/mL IFN- $\gamma$ , 10 ng/mL TNF- $\alpha$ , and 5 ng/mL  
240 IL-1 $\beta$ ) for 24 h in combination with a variety of fatty acids at 400  $\mu$ M: oleate (18:1),  
241 stearate (18:0), palmitate (16:0), arachidonate (20:4), linoleate (18:2),  
242 docosahexaenoate (22:6) and eicosapentaenoate (20:5). While stearate, palmitate and  
243 linoleate had minimal to no effect on MIN6 cells without cytokines, they synergistically  
244 enhanced the cytokine-mediated apoptosis (**Fig. 3A**). Conversely, arachidonate and  
245 eicosapentaenoate reduced apoptosis in both cells treated or not treated with CT2 (**Fig.**  
246 **3A**). As palmitate had the strongest effect and was also released by LIPG in islets, it  
247 was chosen for the remaining experiments. We treated MIN6 cells with various  
248 concentrations of palmitate (50-800  $\mu$ M) in combination with CT2 for 24 h and measured  
249 apoptosis. The palmitate treatment itself had no effect on  $\beta$ -cell apoptosis up to 400  $\mu$ M,  
250 but concentrations as low as 200  $\mu$ M significantly enhanced the apoptosis induced by  
251 CT2 (**Fig. 3B**). These results showed that FFAs increase cytokine-mediated apoptosis.

### 252 ***NAMPT as a regulator of FFA-enhanced cytokine-mediated apoptosis***

253 To identify possible mechanisms of FFA enhancement of cytokine-mediated apoptosis,  
254 we performed a proteomics analysis of MIN6 cells treated with CT2 + 400  $\mu$ M palmitate,  
255 leading to the identification of 6049 proteins (**Supplemental Table 5**). The CT2  
256 treatment itself regulated the levels of 631 proteins (86 upregulated and 545  
257 downregulated), while the palmitate treatment itself regulated the levels of 262 proteins  
258 (10 upregulated and 252 downregulated) (**Supplemental Table 6-7**). The CT2 +  
259 palmitate vs. CT2 comparison resulted in abundance changes of 261 proteins (45 and  
260 216 proteins upregulated and downregulated, respectively) (**Fig. 3C, Supplemental**  
261 **Table 8**). A functional-enrichment analysis of this comparison identified 48 pathways to  
262 be significantly enriched among the regulated proteins (**Fig. 3D**). This included



263 metabolic pathways (e.g. oxidative phosphorylation, amino sugar and nucleotide sugar  
264 metabolism, insulin signaling pathway), cell-death pathways (e.g. necroptosis, NOD-like  
265 receptor signaling pathway) and immune response pathways (e.g. PD-L1 expression,  
266 human cytomegalovirus infection).

267 We next investigated possible mechanisms of apoptosis enhancement by the CT2 +  
268 palmitate treatment. In the proteomics analysis, the NOD-like receptor signaling  
269 pathway was the one directly involved in apoptosis among those regulated when  
270 comparing CT2 + palmitate vs. CT2 conditions (**Fig. 3D**). One standout member of this  
271 pathway was nicotinamide phosphoribosyltransferase, NAMPT, whose levels were  
272 upregulated 4.5-fold in cells treated with CT2 and diminished by 0.6-fold following  
273 addition of palmitate to the CT2 treatment (**Fig. 4A**). NAMPT is also the rate-limiting  
274 enzyme of the intracellular nicotinamide adenosine dinucleotide (NAD) salvage  
275 biosynthesis pathway. To test the role of NAMPT depletion in enhancing CT2-mediated  
276 apoptosis, we treated MIN6 cells with its inhibitor FK866 in combination with CT2. The  
277 inhibition of NAMPT induced a phenotype similar to that of palmitate-induced  
278 enhancement of CT2-mediated apoptosis, which was abolished by supplementing the  
279 cells with nicotinamide riboside (NR) (**Fig. 4B**), a metabolite downstream from NAMPT  
280 in the NAD salvage pathway. We next measured the levels of NAD in FK866-treated  
281 cells, which confirmed that FK866 causes depletion of NAD and that its production was  
282 rescued by the addition of NR (**Fig. 4C**). We treated MIN6 cells with CT2 + palmitate in  
283 combination with NR and measured both apoptosis and NAD levels. The NR  
284 supplementation failed to rescue both the apoptosis enhancement by palmitate (**Fig.**  
285 **4D**) and the recovery of cellular NAD levels (**Fig. 4E**). These data show that palmitate  
286 enhances cytokine-mediated apoptosis via downregulation of NAMPT and depletion of  
287 NAD levels. However, NR supplementation fails to rescue the cells from apoptosis,  
288 suggesting that additional factors are involved.

### 289 ***Deregulation of the central carbon metabolism by cytokines + palmitate reduces*** 290 ***cellular ATP levels***

291 We next investigated possible additional factors that impair NR from rescuing cells from  
292 the cytokine-mediated apoptosis enhanced by palmitate. The insulin receptor signaling  
293 pathway, which regulates glycolysis, was one of the pathways identified as  
294 downregulated in the proteomics analysis comparing the CT2 + palmitate vs. CT2  
295 conditions (**Fig. 3C**). Eight proteins of this pathway were downregulated, including the  
296 glycolysis rate-limiting enzyme hexokinase 1 (HK1) (**Fig. 5A**). In MIN6 cells, the CT2  
297 treatment alone decreased the level of HK1 by 1.6-fold, but the combination of CT2 +  
298 palmitate reduced the levels of HK1 by 33% (**Fig. 5B**). To investigate possible  
299 consequences of this regulation on central carbon metabolism, we performed a GC-MS  
300 metabolomics analysis of MIN6 cells treated with the combination of CT2 + palmitate for  
301 8 h. The palmitate treatment alone only reduced the levels of lactate (**Fig. 5C**), while

302 CT2 treatment alone induced a trend for increasing the glycolytic activity with elevated  
303 but not significant pyruvate concentration (**Fig. 5C**). The combined CT2 + palmitate  
304 treatment led to an increase in phosphoenolpyruvate and reduction in lactate levels  
305 compared to the control (**Fig. 5C**). Downstream, there was an increase in the late TCA  
306 cycle metabolites  $\alpha$ -ketoglutarate, malate and fumarate comparing the CT2 + palmitate  
307 vs. the CT2 alone conditions (**Fig. 5C**). There is an increase in glutamate and glutamine  
308 (**Fig. 5C**), suggesting an overflow from the central carbon metabolism towards the  
309 amino acid metabolism.

310 Next, we measured the levels of ATP to determine how these changes in the central  
311 carbon metabolism affect energy production. The ATP level was reduced by 8% in cells  
312 treated solely with palmitate and by 20% in cells treated with CT2. The CT2 + palmitate  
313 treatment reduced ATP by 38% (**Fig. 5E**), showing that cellular energy production is  
314 compromised. To test the role of HK1 in the regulation of the CT2 + palmitate enhanced  
315 apoptosis, we treated the cells with the HK1 inhibitor lonidamine. The treatment  
316 enhanced the CT2-mediated apoptosis in MIN6 by 1.25-fold (**Fig. 5D**). However, a  
317 similar increase was also observed in cells not treated with cytokines (1.4-fold increase)  
318 (**Fig. 5D**), suggesting that HK1 is not responsible for the enhancement of cytokine-  
319 mediated apoptosis by palmitate. These results show that downregulation of HK1 is not  
320 responsible for enhancement of cytokine-mediated apoptosis by palmitate. However,  
321 FFA in combination with cytokines affected central carbon metabolism and ATP  
322 production, which might contribute to the depletion of NAD as the salvage pathway  
323 requires ATP.

### 324 ***Downregulation of the NAD salvage pathway and central carbon metabolism in $\beta$*** 325 ***cells during T1D development***

326 To study if the NAD salvage pathway and central carbon metabolism regulation may  
327 occur *in vivo* during T1D development, we analyzed the islet single cell RNA seq data  
328 from human donors in different stages of T1D development<sup>42</sup>. These data contained  
329 quantitative sequencing information from 12,660  $\beta$  cells, including 4,710 from non-  
330 diabetic donors, 4,156 from donors with single islet autoantibodies, 2,521 from donors  
331 with multiple islet autoantibodies, and 1,273 from donors with T1D. In the NAD salvage  
332 pathway, we found that NAMPT expression is higher in  $\beta$  cells of non-diabetic donors,  
333 and significantly reduced in individuals with single or multiple autoantibodies (**Fig. 6A**).  
334 In central carbon metabolism, there is a downregulation of 12 of the 20 detected  
335 transcripts of the glycolytic pathway in  $\beta$  cells in individuals with one or multiple islet  
336 autoantibodies (**Fig. 6B**). After the onset of the disease, the levels of the glycolytic  
337 enzymes are slightly higher with the transcripts of 3 enzymes upregulated (**Fig. 6B**). A  
338 similar pattern is observed in the TCA cycle, with the expression of 12 enzymes reduced  
339 in individuals positive for one or multiple autoantibodies, and 4 enzymes increased after  
340 the onset of the disease (**Fig. 6C**). These results show that the expression of the

341 components of the NAD salvage pathway, glycolysis, and TCA cycle are downregulated  
342 in  $\beta$  cells during T1D development, supporting our *in vitro* findings.

343

344

345

## 346 **Discussion**

347 Our current and previous data<sup>16</sup> show that CT1 reduced the levels of triacylglycerols,  
348 which was associated to LIPG upregulation and their digestion into FFAs. In the TEDDY  
349 plasma lipidomics data, there is a similar pattern with decrease in triacylglycerols and  
350 phosphatidylcholines and an increase in FFAs at 3 months post-seroconversion.  
351 Although some of the increases in FFA levels are moderate, we found that  
352 concentrations as low as 200  $\mu$ M of palmitate enhances cytokine-mediated apoptosis.  
353 Considering that the basal levels of palmitate in plasma are around 145  $\mu$ M<sup>44</sup>, even  
354 small changes in FFA concentration might have a deleterious effect when combined  
355 with the local pro-inflammatory cytokines present during insulinitis in a chronic disease.

356 Regarding specific plasma lipoproteins, ApoA1 and ApoA2 (which were regulated in the  
357 proteomics analysis) are major components of HDL and chylomicrons<sup>45</sup>, but LIPG being  
358 an HDL lipase<sup>46</sup>, making more likely that high-density lipoprotein (HDL) is involved in the  
359 process. HDL is also the particle richest in phospholipids<sup>45</sup>, and is a possible source of  
360 the phosphatidylcholines digested after seroconversion. Likewise, HDL decreases after  
361 seroconversion but returns to basal levels after T1D diagnosis, suggesting a temporary  
362 regulation<sup>47</sup>. ApoB was also reduced after seroconversion in our proteomics analysis.  
363 This protein has two major isoforms, the full-length ApoB-100, enriched in low-density  
364 lipoprotein (LDL) and very low-density lipoprotein (VLDL), and ApoB-48, enriched in  
365 chylomicrons<sup>45</sup>. Unfortunately, our bottom-up proteomics analysis does not distinguish  
366 between the two isoforms. Considering that all three particles are rich in  
367 triacylglycerols<sup>45</sup>, each could be the source of the triacylglycerols that are digested after  
368 seroconversion. During islet autoimmunity, LDL levels remain unaltered but are  
369 increased later<sup>47</sup>.

370 Regarding lipases involved in the fatty acid release, LIPG is a cell surface lipoprotein  
371 lipase that digests lipids from HDL and facilitates the uptake of fatty acids by cells<sup>43</sup>.  
372 LIPG also helps to dock and internalize HDL, LDL, VLDL particles by cells<sup>43</sup>. LIPC is  
373 less likely to be involved as its regulation is mainly via transcription<sup>48</sup> and its levels in the  
374 proteomics analysis remained unaltered. LPL protein levels also remained unaltered,  
375 but its activity might be enhanced by the observed reduction in its inhibitors ApoC1 and  
376 ApoC3. Low ApoC1 is associated with progression to T1D before the age of 5 years<sup>49</sup>.  
377 There is a similar pattern of ApoC1 in the TEDDY NCC1, where its reduction was

378 associate with the development of T1D by the age of 6 years<sup>15</sup>. LIPG and LPL might  
379 work sequentially to digest triacylglycerols and phosphatidylcholines, as LIPG mainly  
380 cleaves fatty acyl groups at the *sn-1* position into diacylglycerols and  
381 lysophosphatidylcholines<sup>43</sup>. These intermediates largely remained unaltered in the  
382 process, suggesting that they are being cleaved by the action of additional lipase(s).

383 Both LIPG and LPL play relevant roles in inflammation. In macrophages, LIPG mediates  
384 toll-like receptors 3 and 4 signaling by repressing and inducing the expression of anti-  
385 and pro-inflammatory genes, respectively<sup>43</sup>. LPL enhances interferon- $\gamma$ -induced pro-  
386 inflammatory signaling in endothelial cells<sup>50</sup>. Our results show that released FFAs  
387 enhance cytokine-mediated apoptosis in MIN6 cells, which involves the depletion of  
388 NAD. Pro-inflammatory cytokines induce an upregulation of the NAD *de novo* synthesis  
389 pathway in human islets<sup>51</sup>. This pathway promotes an efficient inflammatory response  
390 by fueling the cell with NAD<sup>52</sup>, and might provide the NAD needed during insulinitis. Our  
391 data show that the combination of CT2 + palmitate inhibits the NAD salvage pathway,  
392 depleting cellular NAD. In the body, the *de novo* synthesis pathway is particularly active  
393 in the liver, while other tissues rely mostly on the salvage pathway<sup>53</sup>. This agrees with  
394 the strong impact we observed in cells treated with cytokines + palmitate. In  
395 hepatocytes, palmitate downregulates the expression of NAMPT, leading to apoptosis<sup>54</sup>.  
396 However, in contrast to our observations, the hepatocyte apoptosis is reversed by the  
397 addition of nicotinamide mononucleotide, a metabolite downstream from NAMPT in the  
398 NAD salvage pathway<sup>54</sup>. In our experimental condition, the cells are not rescued with  
399 NR, another metabolite downstream from NAMPT in the NAD salvage pathway.

400 We found that the combination of FFAs with cytokines induced major changes cellular  
401 central carbon metabolism. The cells treated with cytokines + palmitate had an  
402 unproductive accumulation of various glycolytic and TCA cycle intermediates, leading to  
403 reduction in cellular ATP levels. This might explain the inability to rescue the cells with  
404 NR, as both enzymes of the salvage pathway, NAMPT and NMNAT, require ATP to  
405 catalyze their reactions. Therefore, the deregulation in central carbon metabolism  
406 further aggravates the impairment in the NAD salvage pathway<sup>55</sup>. Overall, our data  
407 show that inflammation leads to a release in FFAs, which aggravates cytokine-mediated  
408 apoptosis. This process was associated with the development of T1D at a young age  
409 (<6 years). The mechanism involves depletion of cellular NAD levels by impairing its  
410 recycling via the salvage pathway, which is further aggravated by deregulation of central  
411 carbon metabolism leading to reduced ATP production.

412

### 413 **Competing interests**

414 The authors declare that they have no competing interests.

415

## 416 **Acknowledgments**

417 Part of the work was performed in the Environmental Molecular Sciences Laboratory, a  
418 U.S. DOE national scientific user facility at Pacific Northwest National Laboratory  
419 (PNNL) in Richland, WA. Battelle operates PNNL for the DOE under contract DE-AC05-  
420 76RLO01830. This work was supported by the Catalyst Award from the Human Islet  
421 Research Network (HIRN) (to E.S.N.) (via U24 DK104162) and by National Institutes of  
422 Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)  
423 grants R01 DK138335 (to E.S.N., M.R., B.J.M.W.R and T.O.M.), U01 DK127505 (to  
424 E.S.N.), U01 DK127786 (to R.G.M, D.L.E, B.J.M.W.R and T.O.M.), R01 DK060581 (to  
425 R.G.M.), R01 DK105588 (to R.G.M.) The TEDDY Study is funded by U01 DK63829,  
426 U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01  
427 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4  
428 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4  
429 DK112243, UC4 DK117483, U01 DK124166, U01 DK128847, and Contract No.  
430 HHSN267200700014C from the NIDDK, National Institute of Allergy and Infectious  
431 Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and  
432 Human Development (NICHD), National Institute of Environmental Health Sciences  
433 (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF. This work is  
434 supported in part by the NIH/NCATS Clinical and Translational Science Awards to the  
435 University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR002535).  
436 The content is solely the responsibility of the authors and does not necessarily  
437 represent the official views of the National Institutes of Health.

438

## 439 **Data availability**

440 The TEDDY lipidomics data are available at the Metabolomics Workbench repository  
441 under project ID PR000950 and doi 10.21228/M8WM4P. The GC-MS data were  
442 uploaded into the Open Science Framework under accession number 86u3m  
443 (<https://osf.io/86u3m/>). The proteomics data were deposited into the MassIVE  
444 repository, a member of the ProteomeXchange, under accession number  
445 MSV000095733.

446

## 447 References

- 448 1. Beran, D., *et al.* A plan to improve global type 1 diabetes epidemiology data.  
449 *Lancet Diabetes Endocrinol* **11**, 154-155 (2023).
- 450 2. Gregory, G.A., *et al.* Global incidence, prevalence, and mortality of type 1  
451 diabetes in 2021 with projection to 2040: a modelling study. *Lancet Diabetes*  
452 *Endocrinol* **10**, 741-760 (2022).
- 453 3. Huo, L., Harding, J.L., Peeters, A., Shaw, J.E. & Magliano, D.J. Life expectancy  
454 of type 1 diabetic patients during 1997-2010: a national Australian registry-based  
455 cohort study. *Diabetologia* **59**, 1177-1185 (2016).
- 456 4. DiMeglio, L.A., Evans-Molina, C. & Oram, R.A. Type 1 diabetes. *Lancet* **391**,  
457 2449-2462 (2018).
- 458 5. Atkinson, M.A., Eisenbarth, G.S. & Michels, A.W. Type 1 diabetes. *Lancet* **383**,  
459 69-82 (2014).
- 460 6. Veijola, R., *et al.* HLA-DQB1-defined genetic susceptibility, beta cell  
461 autoimmunity, and metabolic characteristics in familial and nonfamilial insulin-  
462 dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group.  
463 *J Clin Invest* **98**, 2489-2495 (1996).
- 464 7. Baisch, J.M., *et al.* Analysis of HLA-DQ genotypes and susceptibility in insulin-  
465 dependent diabetes mellitus. *N Engl J Med* **322**, 1836-1841 (1990).
- 466 8. Sanjeevi, C.B., *et al.* Polymorphic amino acid variations in HLA-DQ are  
467 associated with systematic physical property changes and occurrence of IDDM.  
468 Members of the Swedish Childhood Diabetes Study. *Diabetes* **44**, 125-131  
469 (1995).
- 470 9. Rewers, M. & Ludvigsson, J. Environmental risk factors for type 1 diabetes.  
471 *Lancet* **387**, 2340-2348 (2016).
- 472 10. Lamichhane, S., *et al.* Dynamics of Plasma Lipidome in Progression to Islet  
473 Autoimmunity and Type 1 Diabetes - Type 1 Diabetes Prediction and Prevention  
474 Study (DIPP). *Sci Rep* **8**, 10635 (2018).
- 475 11. Ferrara-Cook, C., *et al.* Excess BMI Accelerates Islet Autoimmunity in Older  
476 Children and Adolescents. *Diabetes Care* **43**, 580-587 (2020).
- 477 12. Lamichhane, S., *et al.* Dysregulation of secondary bile acid metabolism precedes  
478 islet autoimmunity and type 1 diabetes. *Cell Rep Med* **3**, 100762 (2022).
- 479 13. Nelson, A.J., *et al.* Lipid mediators and biomarkers associated with type 1  
480 diabetes development. *JCI Insight* **5**(2020).
- 481 14. Diaz Ludovico, I., *et al.* Fatty acid-mediated signaling as a target for developing  
482 type 1 diabetes therapies. *Expert Opin Ther Targets* **27**, 793-806 (2023).
- 483 15. Nakayasu, E.S., *et al.* Plasma protein biomarkers predict the development of  
484 persistent autoantibodies and type 1 diabetes 6 months prior to the onset of  
485 autoimmunity. *Cell Rep Med* **4**, 101093 (2023).
- 486 16. Sarkar, S., *et al.* Regulation of beta-cell death by ADP-ribosylhydrolase ARH3 via  
487 lipid signaling in insulinitis. *Cell Commun Signal* **22**, 141 (2024).
- 488 17. Yuan, X., *et al.* Functional and metabolic alterations of gut microbiota in children  
489 with new-onset type 1 diabetes. *Nat Commun* **13**, 6356 (2022).
- 490 18. Bi, X., *et al.* omega-3 polyunsaturated fatty acids ameliorate type 1 diabetes and  
491 autoimmunity. *J Clin Invest* **127**, 1757-1771 (2017).

- 492 19. Lo Conte, M., *et al.* A diet enriched in omega-3 PUFA and inulin prevents type 1  
493 diabetes by restoring gut barrier integrity and immune homeostasis in NOD mice.  
494 *Front Immunol* **13**, 1089987 (2022).
- 495 20. Norris, J.M., *et al.* Omega-3 polyunsaturated fatty acid intake and islet  
496 autoimmunity in children at increased risk for type 1 diabetes. *JAMA* **298**, 1420-  
497 1428 (2007).
- 498 21. Group, T.S. The Environmental Determinants of Diabetes in the Young (TEDDY)  
499 Study. *Ann N Y Acad Sci* **1150**, 1-13 (2008).
- 500 22. Johnson, S.B., *et al.* The Environmental Determinants of Diabetes in the Young  
501 (TEDDY) study: predictors of early study withdrawal among participants with no  
502 family history of type 1 diabetes. *Pediatr Diabetes* **12**, 165-171 (2011).
- 503 23. Hagopian, W.A., *et al.* The Environmental Determinants of Diabetes in the Young  
504 (TEDDY): genetic criteria and international diabetes risk screening of 421 000  
505 infants. *Pediatr Diabetes* **12**, 733-743 (2011).
- 506 24. Lee, H.S., *et al.* Biomarker discovery study design for type 1 diabetes in The  
507 Environmental Determinants of Diabetes in the Young (TEDDY) study. *Diabetes*  
508 *Metab Res Rev* **30**, 424-434 (2014).
- 509 25. Li, Q., *et al.* Plasma Metabolome and Circulating Vitamins Stratified Onset Age of  
510 an Initial Islet Autoantibody and Progression to Type 1 Diabetes: The TEDDY  
511 Study. *Diabetes* **70**, 282-292 (2021).
- 512 26. Li, Q., *et al.* Longitudinal Metabolome-Wide Signals Prior to the Appearance of a  
513 First Islet Autoantibody in Children Participating in the TEDDY Study. *Diabetes*  
514 **69**, 465-476 (2020).
- 515 27. Webb-Robertson, B.M., *et al.* Prediction of the development of islet  
516 autoantibodies through integration of environmental, genetic, and metabolic  
517 markers. *J Diabetes* **13**, 143-153 (2021).
- 518 28. Fan, S., *et al.* Systematic Error Removal Using Random Forest for Normalizing  
519 Large-Scale Untargeted Lipidomics Data. *Anal Chem* **91**, 3590-3596 (2019).
- 520 29. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical  
521 and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical*  
522 *Society: Series B (Methodological)* **57**, 289-300 (1995).
- 523 30. Nakayasu, E.S., *et al.* Comprehensive Proteomics Analysis of Stressed Human  
524 Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention. *Cell Metab*  
525 **31**, 363-374 e366 (2020).
- 526 31. Nakayasu, E.S., *et al.* MPLEx: a Robust and Universal Protocol for Single-  
527 Sample Integrative Proteomic, Metabolomic, and Lipidomic Analyses. *mSystems*  
528 **1**(2016).
- 529 32. Kim, Y.M., *et al.* Salmonella modulates metabolism during growth under  
530 conditions that induce expression of virulence genes. *Mol Biosyst* **9**, 1522-1534  
531 (2013).
- 532 33. Hiller, K., *et al.* MetaboliteDetector: comprehensive analysis tool for targeted and  
533 nontargeted GC/MS based metabolome analysis. *Anal Chem* **81**, 3429-3439  
534 (2009).
- 535 34. Kind, T., *et al.* FiehnLib: mass spectral and retention index libraries for  
536 metabolomics based on quadrupole and time-of-flight gas chromatography/mass  
537 spectrometry. *Anal Chem* **81**, 10038-10048 (2009).


- 538 35. Junker, B.H., Klukas, C. & Schreiber, F. VANTED: a system for advanced data  
539 analysis and visualization in the context of biological networks. *BMC*  
540 *Bioinformatics* **7**, 109 (2006).
- 541 36. Sarkar, S., *et al.* Regulation of  $\beta$ -cell death by ADP-ribosylhydrolase ARH3 via  
542 lipid signaling in insulinitis. *Cell Commun Signal* **In press**.
- 543 37. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates,  
544 individualized p.p.b.-range mass accuracies and proteome-wide protein  
545 quantification. *Nat Biotechnol* **26**, 1367-1372 (2008).
- 546 38. Tyanova, S., *et al.* The Perseus computational platform for comprehensive  
547 analysis of (prote)omics data. *Nature Methods* **13**, 731-740 (2016).
- 548 39. Tyanova, S., *et al.* The Perseus computational platform for comprehensive  
549 analysis of (prote)omics data. *Nat Methods* **13**, 731-740 (2016).
- 550 40. Huang da, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative  
551 analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**,  
552 44-57 (2009).
- 553 41. Fasolino, M., *et al.* Single-cell multi-omics analysis of human pancreatic islets  
554 reveals novel cellular states in type 1 diabetes. *Nat Metab* **4**, 284-299 (2022).
- 555 42. Kaestner, K.H., Powers, A.C., Naji, A., Consortium, H. & Atkinson, M.A. NIH  
556 Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in  
557 Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP). *Diabetes* **68**,  
558 1394-1402 (2019).
- 559 43. Yu, J.E., Han, S.Y., Wolfson, B. & Zhou, Q. The role of endothelial lipase in lipid  
560 metabolism, inflammation, and cancer. *Histol Histopathol* **33**, 1-10 (2018).
- 561 44. Persson, X.M., Blachnio-Zabielska, A.U. & Jensen, M.D. Rapid measurement of  
562 plasma free fatty acid concentration and isotopic enrichment using LC/MS. *J*  
563 *Lipid Res* **51**, 2761-2765 (2010).
- 564 45. Bhargava, S., de la Puente-Secades, S., Schurgers, L. & Jankowski, J. Lipids  
565 and lipoproteins in cardiovascular diseases: a classification. *Trends Endocrinol*  
566 *Metab* **33**, 409-423 (2022).
- 567 46. Ishida, T., *et al.* Endothelial lipase is a major determinant of HDL level. *J Clin*  
568 *Invest* **111**, 347-355 (2003).
- 569 47. Aulanni'am, A., *et al.* The early detection of type 1 diabetes mellitus and latent  
570 autoimmune diabetes in adults (LADA) through rapid test reverse-flow  
571 immunochromatography for glutamic acid decarboxylase 65 kDa (GAD(65)).  
572 *Heliyon* **8**, e08695 (2022).
- 573 48. Rufibach, L.E., Duncan, S.A., Battle, M. & Deeb, S.S. Transcriptional regulation  
574 of the human hepatic lipase (LIPC) gene promoter. *J Lipid Res* **47**, 1463-1477  
575 (2006).
- 576 49. Hirvonen, M.K., *et al.* Serum APOC1 levels are decreased in young autoantibody  
577 positive children who rapidly progress to type 1 diabetes. *Sci Rep* **13**, 15941  
578 (2023).
- 579 50. Kota, R.S., Ramana, C.V., Tenorio, F.A., Enelow, R.I. & Rutledge, J.C. Differential  
580 effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-  
581 gamma-mediated gene expression in human endothelial cells. *J Biol Chem* **280**,  
582 31076-31084 (2005).



- 583 51. Garcia-Contreras, M., *et al.* Metabolomics Study of the Effects of Inflammation,  
584 Hypoxia, and High Glucose on Isolated Human Pancreatic Islets. *J Proteome*  
585 *Res* **16**, 2294-2306 (2017).
- 586 52. Minhas, P.S., *et al.* Macrophage de novo NAD(+) synthesis specifies immune  
587 function in aging and inflammation. *Nat Immunol* **20**, 50-63 (2019).
- 588 53. Liu, L., *et al.* Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. *Cell*  
589 *Metab* **27**, 1067-1080 e1065 (2018).
- 590 54. Penke, M., *et al.* Oleate ameliorates palmitate-induced reduction of NAMPT  
591 activity and NAD levels in primary human hepatocytes and hepatocarcinoma  
592 cells. *Lipids Health Dis* **16**, 191 (2017).
- 593 55. Mehmel, M., Jovanovic, N. & Spitz, U. Nicotinamide Riboside-The Current State  
594 of Research and Therapeutic Uses. *Nutrients* **12**(2020).
- 595
- 596

597 Figure 1

598




599

600 **Figure 1:** Profiles of endothelial lipase LIPG (A) and free palmitate (B) in human islets treated  
601 with cytokines IL-1 $\beta$  and IFN- $\gamma$  (CT1) for 24 h. LIPG was measured by proteomics analysis while  
602 palmitate by gas chromatography-mass spectrometry analysis. NoCT – untreated control. \*\*  
603 Paired Student's *t*-test  $p \leq 0.01$ .

604

605 Figure 2




606

607 **Figure 2** – Plasma lipid and lipoprotein profile on during T1D development. Lipid and protein  
 608 profiles were obtained from lipidomics and proteomics measurements of the TEDDY nested  
 609 case-control study 1 (NCC1), which comprises of time point sample collections from children up  
 610 to the age of 6 years. (A) Heatmap of representative, significant species of phosphatidylcholines  
 611 (PC) and triacylglycerols (TG). (B) Heatmap of all quantified intermediates of PC and TG,  
 612 lysophosphatidylcholine (LPC) and diacylglycerol (DG), respectively. (C) Heatmap of  
 613 representative, significant species of PC and TG digestion products, acyl-carnitines (AC) and  
 614 (free) fatty acids (FA), respectively. Additional abbreviations: ApoA1 – apolipoprotein A1, ApoA2  
 615 – apolipoprotein A2, ApoC1 – apolipoprotein C1, ApoC2 – apolipoprotein C2, ApoC3 –  
 616 apolipoprotein C3, LIPC – hepatic lipase, LPL – lipoprotein lipase, Pre-SC – pre-seroconversion,  
 617 Post-SC – post-seroconversion. \*Student's *t*-test  $\leq 0.05$ .

618


619

620 Figure 3




621  
 622 **Figure 3.** Enhancement of cytokine-mediated apoptosis by palmitic acid. **(A)** MIN6 cells were  
 623 treated for 24 h with a cytokine cocktail (CT2: 100 ng/mL IFN- $\gamma$ , 10 ng/mL TNF- $\alpha$ , and 5 ng/mL  
 624 IL-1 $\beta$ ) in combination with various types of fatty acids at a concentration of 400  $\mu$ M: oleate,  
 625 stearate, palmitate, arachidonate, linoleate, docosahexaenoate, eicosapentaenoate and  
 626 apoptosis levels measured by caspase 3/7 activity using a luminescent assay. **(B)** The cells  
 627 were treated with CT2 in combination with various concentrations of palmitate and apoptosis  
 628 was measured. **(C)** Heatmap of significant proteins comparing CT2 vs. CT2 + 400  $\mu$ M palmitate.  
 629 **(D)** Function enrichment analysis of significant proteins comparing CT2 vs. CT2 + palmitate.  
 630 Additional abbreviations: NoCT – no cytokine treatment control, Eth – ethanol vehicle control. 2-

631 way ANOVA, Šídák's multiple comparisons test: \* $p \leq 0.05$ , \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ , \*\*\*\*  $p \leq$   
 632 0.0001.




633

634 **Figure 4** – Regulation of NAD metabolism in cytokine-mediated apoptosis by palmitate. MIN6  
 635 cells were treated with cytokine cocktail (CT2: 100 ng/mL IFN- $\gamma$ , 10 ng/mL TNF- $\alpha$ , and 5 ng/mL  
 636 IL-1 $\beta$ ) in combination with 400  $\mu$ M palmitate. (A) Levels of NAMPT measured by proteomics  
 637 analysis. Levels of apoptosis (measured by caspase 3/7 activity) (B) and NAD (C) in cells  
 638 treated with CT2 in combination with 10  $\mu$ M NAMPT inhibitor FK866 and 100  $\mu$ M nicotinamide  
 639 ribose (NR). Levels of apoptosis (measured by caspase 3/7 activity) (D) and NAD (E) in cells  
 640 treated with CT2 + 400 $\mu$ M palmitate in combination with 100  $\mu$ M NR. Additional abbreviations:  
 641 NoCT – no cytokine treatment control, Eth – ethanol vehicle control. 2-way ANOVA, Šídák's  
 642 multiple comparisons test: \* $p \leq 0.05$ , \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ , \*\*\*\*  $p \leq 0.0001$ .



643

644 **Figure 5** – Regulation of the central carbon metabolism by the cytokine cocktail (CT2: 100  
 645 ng/mL IFN- $\gamma$ , 10 ng/mL TNF- $\alpha$ , and 5 ng/mL IL-1 $\beta$ ) + palmitate. **(A)** Enrichment of palmitate +  
 646 CT2-regulated proteins onto the insulin receptor signaling pathway using IPA. **(B)** Hexokinase 1  
 647 HK1 protein level measured by proteomic analysis. Levels of apoptosis (measured by caspase  
 648 3/7 activity) **(C)** in MIN6 cells treated with CT2 with or without 400  $\mu$ M palmitate in combination  
 649 with 200  $\mu$ M hexokinase inhibitor lonidamine and 100  $\mu$ M nicotinamide riboside (NR). **(D)** Level  
 650 of various metabolites from the central carbon metabolism measured using GC-MS in MIN6 cell  
 651 treated with CT2 + 400  $\mu$ M palmitate. **(E)** Level of ATP measured in MIN6 cell treated with CT2  
 652 + 400  $\mu$ M palmitate. Additional abbreviations: NoCT – no cytokine treatment control, Eth –  
 653 ethanol vehicle control. T-test **(D)**, 2-way ANOVA, Šídák's multiple comparisons test **(B, C, & E)**:  
 654 \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ , \*\*\*\*  $p \leq 0.0001$ .



655

656 **Figure 6** – Expression of genes from the NAD salvage pathway, glycolysis/gluconeogenesis  
 657 and TCA cycle during different stages of type 1 diabetes development. The data were  
 658 downloaded from the Human Pancreas Analysis Program (HPAP) data portal  
 659 (<https://hpap.pmacs.upenn.edu/>) and processed as described in material and methods.  
 660 Abbreviations: AAB1+ - individuals seropositive for 1 islet autoantibody, AAB2+ - individuals  
 661 seropositive for multiple islet autoantibodies, beta –  $\beta$  cells, T1D – type 1 diabetes.